Background and aim: Escherichia coli Nissle (ECN) 1917 is a Gramnegativebacteria that belongs to the family of Enterobacteriaceae,and it is currently used as probiotic drug in the managementof infectious gastroenteritis and in maintenance of remission inulcerative colitis (UC) patients. ECN has been described to act alsoon intestinal epithelial barrier but few information exists on theinfluence of this probiotic on the gut microbiota composition.Material and methods: Five patients affected by UC were treatedwith ECN (1 pill daily) for 10 days follwed by 2 pills per day forfurther 20 days. Fecal samples were collected before starting thetreatment (T0), after 10 days from the beginning of the therapy (T1)and one month following the start of treatment (T2).Genomic DNA was isolated from the entire set of samples. TheV1-V3 region of 16S rRNA locus was amplified on a 454-JuniorGenome Sequencer. Reads were analyzed by Quantitative Insightsinto Microbial Ecology (QIIME, v.1.8.0), grouped into operationaltaxonomic units (OTUs) by sequence matching against Greengenesdatabase. The α and β diversity and the Kruskal Wallis test wereperformed by QIIME software.Results: The T test on good’s coverage index (measure of totalnumber of species represented in a sample) revealed that thequalitative composition of the gut microbiota between the T0 andT2 conditions resulted significantly different. Box plot of Shannonand Chao I indices revealed an increase in the median indexvalues at the time point T1, which means an increase in theOTU total number at T1. This indicates an increase of the microbiotawellness at this time point. Post hoc analysis at phylumtaxonomic level, revealed that Firmicutes relative abundance inthe condition T0 versus T1 resulted significantly different, with adecrease of Firmicutes at T1. Indeed, at family taxonomic level thepost hoc analysis revealed that Clostridiaceae relative abundancein the condition T0 versus T1, and also in T1 versus T2, differedsignificantly, with a T1 median value higher than the T0 and T2values. At genus level, the T test confirms the variability in thetwo conditions (T0 and T2), with significantly differences for Actinomyces,Anaerostipes, Bacteroides, Bulleidia, Corynebacterium,Dialister, Enterobacteriaceae, Erysipelotrichaceae, Finegoldia, Granulicatella,Lactobacillaceae, Peptoniphilus, Phascolarctobacterium,Roseburia, Serratia, Veillonellaceae, Veillonella_dispar, belonging toFirmicutes, Bacteroidetes and Proteobacteria phyla.Conclusions: Our data show that treatment with ECN leads to an improvement of the qualitative composition of the gut microbiotain patients affected by UC. These effects are stronger at the end oftreatment in terms of wealth, with a stable variability between thegenera after 1 month of treatment.Further studies should be performed to investigate the effect of thisgut microbiota modulation on the history of the disease.
Meeting Abstract: P115
Escherichia coli Nissle 1917 modulate gut microbiota composition in ulcerative colitis patients
Putignani LConceptualization
;
2017-01-01
Abstract
Background and aim: Escherichia coli Nissle (ECN) 1917 is a Gramnegativebacteria that belongs to the family of Enterobacteriaceae,and it is currently used as probiotic drug in the managementof infectious gastroenteritis and in maintenance of remission inulcerative colitis (UC) patients. ECN has been described to act alsoon intestinal epithelial barrier but few information exists on theinfluence of this probiotic on the gut microbiota composition.Material and methods: Five patients affected by UC were treatedwith ECN (1 pill daily) for 10 days follwed by 2 pills per day forfurther 20 days. Fecal samples were collected before starting thetreatment (T0), after 10 days from the beginning of the therapy (T1)and one month following the start of treatment (T2).Genomic DNA was isolated from the entire set of samples. TheV1-V3 region of 16S rRNA locus was amplified on a 454-JuniorGenome Sequencer. Reads were analyzed by Quantitative Insightsinto Microbial Ecology (QIIME, v.1.8.0), grouped into operationaltaxonomic units (OTUs) by sequence matching against Greengenesdatabase. The α and β diversity and the Kruskal Wallis test wereperformed by QIIME software.Results: The T test on good’s coverage index (measure of totalnumber of species represented in a sample) revealed that thequalitative composition of the gut microbiota between the T0 andT2 conditions resulted significantly different. Box plot of Shannonand Chao I indices revealed an increase in the median indexvalues at the time point T1, which means an increase in theOTU total number at T1. This indicates an increase of the microbiotawellness at this time point. Post hoc analysis at phylumtaxonomic level, revealed that Firmicutes relative abundance inthe condition T0 versus T1 resulted significantly different, with adecrease of Firmicutes at T1. Indeed, at family taxonomic level thepost hoc analysis revealed that Clostridiaceae relative abundancein the condition T0 versus T1, and also in T1 versus T2, differedsignificantly, with a T1 median value higher than the T0 and T2values. At genus level, the T test confirms the variability in thetwo conditions (T0 and T2), with significantly differences for Actinomyces,Anaerostipes, Bacteroides, Bulleidia, Corynebacterium,Dialister, Enterobacteriaceae, Erysipelotrichaceae, Finegoldia, Granulicatella,Lactobacillaceae, Peptoniphilus, Phascolarctobacterium,Roseburia, Serratia, Veillonellaceae, Veillonella_dispar, belonging toFirmicutes, Bacteroidetes and Proteobacteria phyla.Conclusions: Our data show that treatment with ECN leads to an improvement of the qualitative composition of the gut microbiotain patients affected by UC. These effects are stronger at the end oftreatment in terms of wealth, with a stable variability between thegenera after 1 month of treatment.Further studies should be performed to investigate the effect of thisgut microbiota modulation on the history of the disease.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
